What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study).

December 8, 2025Blood

GMP-compliant generation, expansion, and a preliminary safety evaluation of CMV-specific t cells using a closed system for post-transplant viral control

View Full Paper

Ask AI

Bookmark

Viral load declined following T cell infusion, indicating improved viral control in the patient.
T cells were expanded using IL-2 in a GMP-compliant process with the Leukoreduction System for high purity.
Cytomegalovirus-specific T cell therapy appears effective and safe even with graft-versus-host disease.
Further investigation of T cell therapy may be warranted for managing viral infections in immunocompromised patients.

No takes yet. Share an insight, caveat, or question.

Phase I trial shows reduced viral load in a patient with refractory CMV infection, indicating safety and potential of T cell therapy.

Marti et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark